For physician-angels · clinicians · early-stage RI investors

RI Life Science Opportunity Atlas

Exhaustive, IP-backed diligence for physician-led formation

A curated map of patent-defined Rhode Island packages—not a generic market scan or deal room. Investable units are patent-defined technology packages. Many are university or hospital assignees with OTL/BRF licensing paths, not standalone incorporated startups.

The atlas is built for formation diligence: which packages can support clinician equity, which need an OTL or hospital license first, and which are better suited to growth equity or strategic exit. Early-stage investors use the same dossiers to align syndicate, angel, and state non-dilutive capital.

RI seed programs typically require co-investors alongside any institutional lead; see Formation policy for match mechanics and per-asset fit—not a term sheet or offering document.

Physician-led formationExplore atlasSample Formation tab

Full atlas corpus: 33 investable units (refreshed Jun 4, 2026). Promise tiers and formation-fit labels are analytical judgments—not investment advice or an offer to sell securities.

What this atlas covers

Qualitative coverage first: why each package exists, how it could be financed, and whether physician-led formation is realistic.

Patent-defined packages
Each investable unit is a technology package anchored in curated USPTO filings—Brown, RIH, URI, or RI companies with clear assignees—not a generic list of local biotech names.
Thorough diligence narrative
Every dossier synthesizes thesis, market context, comparable financing paths, NIH and trial evidence, and license or spinout vehicles so you can judge fit without re-harvesting public databases.
Physician-led formation lens
Formation tabs score early-stage fit, clinician equity models, 18-month milestones, and KOL depth—aligned with RI Clinician-Entrepreneur Network practice and typical third-party match expectations.

Physician-led formation priority

Ranked for clinician-founder potential, active federal signal, and a credible early-stage path with third-party match—not every asset is a new seed formation (growth, royalty, and strategic assets are flagged low in Formation).

Formation fit · high archetype

Tier Aip_iaip_neonatal
IAIP biologics & rapid LFIA for sepsis/NEC/HIE

Dual-path NICU play—IAIP biologic plus rapid LFIA on active SBIR stack.

~$3.7M+ active SBIR—physician-founder equity; Series A $5–10M band vs Inotrem/MeMed.

Entity: ProThera BiologicsPatents: 4Stage: sbir clinical enabling
US7932365B2US9572872B2USRE47972E1US20070297982A1R44AI141283R44NS084575
Open dossier

Formation fit · high

Tier Aip_monaghan_deep_rna_dx
Deep RNA transcriptomic ICU diagnostics (host + pathogen)

One blood draw, full transcriptome—faster pathogen ID than culture, with host splicing biomarkers.

RIH-owned deep RNA platform + NIGMS R35 + Brown RNA Center—physician-founder spinout before national blood-RNA Dx scale-up.

Patents: 4Stage: clinical translational ldt
US20220340972A1US20250034234A1EP4599084A1CN120344677AR35GM142638PMID 41697057
Open dossier

Formation fit · high

Tier Aip_pax_aav_vegf_tendon
AAV2–VEGF gene therapy for tendon & ligament repair (PAX-001)

One-shot gene therapy at repair—faster, stronger tendon healing than surgery alone.

RIH-origin patents + ~$1.7M seed + RILSH LIFT for IND—physician-chairman Liu MD with pre-IND complete.

Entity: Pax TherapeuticsPatents: 1Stage: preclinical ind enabling
WO2019146830A1Source
Open dossier

Formation fit · high

Tier Aip_bolden_musk_neurogenesis
MuSK-pathway ASO neurogenesis (Bolden Therapeutics)

ASO switch for neural stem-cell quiescence—Brown Fallon/Webb science in a Slater-backed Providence newco.

NIA STTR + $1.5M pre-seed (Slater, Lifespan Vision)—formation capital before Big Pharma neurogenesis comparables.

Entity: Bolden TherapeuticsPatents: 3Stage: preclinical in vivo
US12458657B2US20220193114A1WO20200214987A1Source
Open dossier

Formation fit · high

Tier Aip_ecm_morsels_xm
Lab-grown decellularized ECM morsels (injectable matrix therapy)

Injectable human ECM morsels for HF and IPF—Slater-seeded Brown spinout.

Slater $375K + BBII—large-animal PoP before Heartseed-class Series A.

Entity: XM TherapeuticsPatents: 5Stage: preclinical proof of principle
US20230348859A1WO2022140530A1US8361781B2US11286451B2US12435312B2PMID 39705507
Open dossier

Formation fit · high

Tier Aip_nanopieces_rna
Nanopieces non-viral RNA / nanocarrier delivery

Hospital-owned non-viral RNA nanocarriers—STTR-backed with expanded field-of-use option.

RIH assignee + R41TR002298—license to NanoDe or second newco beyond current scope.

Entity: NanoDe TherapeuticsPatents: 4Stage: preclinical sbir
US11701094B2US11608340B2US12357635B2US20230183253A1R41TR002298P20GM104416
Open dossier

Formation fit · high if newco

Tier Bip_biglycan_msk
Biglycan musculoskeletal & neuromuscular regeneration

BRF biglycan MSK regeneration—classic Brown OTL out-license with no RI startup mapped.

Preclinical academic package—physician KOL SAB + Slater seed after PoC.

Patents: 2Stage: preclinical academic
US8658596B2US20110183910A1R21AG073743R21NS112743
Open dossier

Formation fit · medium

Tier Aip_chitinase_ocf203
Chitinase-1 inhibition for pulmonary fibrosis (OCF-203 family)

Chitinase-1 IPF composition with decades of NHLBI P01 support—license diligence on OCF-203.

Brown-origin US11717528B2—sublicense or asset path via Ocean / Elkurt corporate stack.

Entity: Ocean BiomedicalPatents: 1Stage: preclinical to ind
US11717528B2P01HL114501
Open dossier

Formation fit · medium

Tier Aip_wireless_neurograins
Wireless neurograins & distributed cortical implants

DARPA-scale wireless neurograins—dense cortical sensing without Utah-array tethers.

Brown OTL spinout after ~$19M DARPA + UH2—hardware path parallel to BrainGate decode IP.

Patents: 8Stage: preclinical human path
US10433754B2US11464964B2WO2016187254A1WO2020018571A1US20200367749A1US20200229704A1
Open dossier

Formation fit · medium

Tier Aip_speech_tablet_ibci
Speech decoding & multi-device tablet iBCI

Recruiting speech and tablet iBCI trials—decode IP distinct from electrode vendors.

U01 + VA funding with NCT05724173 family—consortium license or device co-development.

Entity: BrainGatePatents: 6Stage: clinical trials recruiting
US12042303US11972050US12561001US10448877B2US18946156U01DC017844
Open dossier

Formation fit · medium

Tier Aip_spinal_isi_dbs
Intelligent spinal interface & closed-loop DBS facilitation

DARPA intelligent spinal interface—SCI rehab IDE distinct from cortical BCI.

DARPA $6.3M + NCT04302259—medtech strategic or SPV vs wireless neurograins.

Patents: 2Stage: early clinical ide
WO2019027517A1US20170042713A1I01RX004250NCT04302259
Open dossier

Formation fit · high if spinout

Tier APatent gapgap_smurf2_oncology
SMURF2–HIF1α oncology

HIF-pathway oncology with Welireg-scale commercial proof—harvest El-Deiry estate.

R01CA173453 + SMURF-Tx Providence—Slater seed after biomarker PoC.

Entity: SMURF-TherapeuticsPatents: 3Stage: preclinical grant
WO2024192252A1US20230183356A1US20230219957A1R01CA173453PMID 39697237PMID 34611473
Open dossier

Per-asset formation notes and ecosystem stack — full formation policy

Recommended workflow

Start with Formation policy
Review what counts as physician-led (equity plus formal KOL advisory—not trial site only), universal 18-month gates, and the RI non-dilutive stack.
Formation policy →
Open a priority dossier
Use the Formation tab for fit, milestones, and capital stack; Value and Evidence for comps and cited grants; People for KOL chips.
Example — ProThera / IAIP →
Stress-test against peers
Comparables matrix places each asset’s market story next to financed benchmark paths and indicative round staging.
Comparables matrix →
Search the full atlas
Explore every unit by modality, tier, or keyword when you need coverage beyond the formation priority queue.
Full opportunity catalog →

Physician-led definition

A Rhode Island life-science venture is physician-led when (1) one or more licensed clinicians hold equity (founder, co-founder, angel/SAB equity, or documented cap-table allocation tied to clinical leadership) AND (2) the company maintains formal KOL advisory roles (paid SAB, clinical advisory board, or RI Clinician-Entrepreneur Network match) that shape indication, endpoints, and trial/site strategy.

Trial site only, uncompensated informal advice, or physician consulting without equity does not qualify for this atlas label.

KOL directory →
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.